IMAGE Skincare has launched VOL.U.LIFT, a new topical solution developed specifically to combat the visible signs of facial ageing linked to GLP-1 weight-loss medications. The formula directly addresses symptoms including volume loss, skin laxity, fine lines, and dehydration. Developed by Dr. Marc Ronert and dermatologist Dr. Raja Sivamani, VOL.U.LIFT offers the first clinically targeted at-home treatment for these increasingly prevalent concerns.
With the rise of GLP-1 drugs such as Ozempic, Wegovy and Mounjaro, the aesthetic side effects of rapid weight loss have become a growing focus. Online search trends reflect heightened demand for solutions to so-called “Ozempic Face”, particularly around facial thinning, crepiness, and texture changes. Clinicians report these effects are due in part to loss of connective tissue, muscle, and reduced levels of collagen and elastin – two proteins essential to skin integrity. The result is often accelerated facial ageing, even as overall health improves.
VOL.U.LIFT is designed to work across four dimensions of skin ageing: restoring visible volume, reinforcing the skin barrier, rehydrating the dermis, and improving surface texture. Powered by IMAGE Skincare’s patent-pending XOSM Technology, it delivers encapsulated antioxidants and active ingredients deeper into the skin for greater efficacy.
Developed following extensive clinical insight into how GLP-1 drugs affect the skin at a cellular level, VOL.U.LIFT is uniquely positioned to support both current users and those seeking a preventative solution. Its multi-dimensional approach makes it a first-of-its-kind formula in the space.
Key ingredients include L-Ornithine Amino Acid to visibly plump sunken areas of the face and improve volume, and HA Silanol, a next-generation hyaluronic acid compound, designed to rehydrate and restore dermal bounce. Bakuchiol provides retinol-like results without irritation, while Kangaroo Paw Extract helps firm and reduce sagging. The formula also includes biomimetic Plant Collagen Fragments, targeting deflated and ageing skin, and XOSM Technology to protect and strengthen the skin’s barrier while delivering high-performance actives.
Initial clinical studies show significant improvement in visible skin volume, texture, and hydration within four weeks of regular use. As the first topical product formulated specifically to address GLP-1-related skin ageing, VOL.U.LIFT provides an effective, evidence-based response to a rapidly emerging concern. With its science-led formulation and focus on targeted skin health, it sets a new standard in precision skincare – one that will only grow in relevance as demand for medically-informed solutions continues to rise.
You can purchase VOL.U.LIFT (RRP £105) directly and with no prescription needed from Wigmore Medical online and instore, and in clinics nationwide. You can find your nearest stockist here.
